Cargando…

Perspective on the Role of Gut Microbiome in the Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors

Background and Objectives: Hepatocellular carcinoma (HCC) is the leading cause of liver cancer worldwide and has a high mortality rate. Its incidence has increased due to metabolic-associated liver disease (MAFLD) epidemics. Liver transplantation and surgery remain the most resolute measures. Despit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abenavoli, Ludovico, Montori, Michele, Svegliati Baroni, Gianluca, Argenziano, Maria Eva, Giorgi, Francesca, Scarlata, Giuseppe Guido Maria, Ponziani, Francesca, Scarpellini, Emidio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10456509/ https://www.ncbi.nlm.nih.gov/pubmed/37629716 http://dx.doi.org/10.3390/medicina59081427

Ejemplares similares

Liver Damage and COVID-19: At Least a “Two-Hit” Story in Systematic Review
por: Montori, Michele, et al.
Publicado: (2023)

The Role of Transjugular Intrahepatic Portosystemic Shunt (TIPS) in Treating Portal Hypertension in Patients with Hepatocellular Carcinoma
por: Balducci, Daniele, et al.
Publicado: (2023)

Farnesoid X Receptor, Bile Acid Metabolism, and Gut Microbiota
por: Mori, Hideki, et al.
Publicado: (2022)

Gut Microbiota and Liver Transplantation: Immune Mechanisms behind the Rejection
por: Abenavoli, Ludovico, et al.
Publicado: (2023)

Human Genes Involved in the Interaction between Host and Gut Microbiome: Regulation and Pathogenic Mechanisms
por: Boccuto, Luigi, et al.
Publicado: (2023)

Gut Microbiota and Critically Ill Patients: Immunity and Its Modulation via Probiotics and Immunonutrition
por: Abenavoli, Ludovico, et al.
Publicado: (2023)

Metabolic-Dysfunction-Associated Fatty Liver Disease and Gut Microbiota: From Fatty Liver to Dysmetabolic Syndrome
por: Abenavoli, Ludovico, et al.
Publicado: (2023)

Ultrasound Prevalence and Clinical Features of Nonalcoholic Fatty Liver Disease in Patients with Inflammatory Bowel Diseases: A Real-Life Cross-Sectional Study
por: Abenavoli, Ludovico, et al.
Publicado: (2023)

Gut Microbiota in Non-Alcoholic Fatty Liver Disease Patients with Inflammatory Bowel Diseases: A Complex Interplay
por: Abenavoli, Ludovico, et al.
Publicado: (2022)

Liver Damage and Impaired Coagulation in COVID-19 Patients: A Case Series
por: Abenavoli, Ludovico, et al.
Publicado: (2023)

Gut Microbiota and Liver Interaction through Immune System Cross-Talk: A Comprehensive Review at the Time of the SARS-CoV-2 Pandemic
por: Scarpellini, Emidio, et al.
Publicado: (2020)

Gut Microbiome in Retina Health: The Crucial Role of the Gut-Retina Axis
por: Scuderi, Gianluca, et al.
Publicado: (2022)

Gut Microbiota and Obesity: A Role for Probiotics
por: Abenavoli, Ludovico, et al.
Publicado: (2019)

Gut-Pancreas-Liver Axis as a Target for Treatment of NAFLD/NASH
por: Svegliati-Baroni, Gianluca, et al.
Publicado: (2020)

Gut Microbiota According to the Metabolome
por: Scarpellini, Emidio, et al.
Publicado: (2023)

Gut Dysbiosis and Fecal Calprotectin Predict Response to Immune Checkpoint Inhibitors in Patients With Hepatocellular Carcinoma
por: Ponziani, Francesca Romana, et al.
Publicado: (2022)

From Pre- and Probiotics to Post-Biotics: A Narrative Review †
por: Scarpellini, Emidio, et al.
Publicado: (2021)

Diagnostic and therapeutic potential of the gut microbiota in patients with early hepatocellular carcinoma
por: Ponziani, Francesca Romana, et al.
Publicado: (2019)

The Apparent Asymmetrical Relationship Between Small Bowel Bacterial Overgrowth, Endotoxemia, and Liver Steatosis and Fibrosis in Cirrhotic and Non-Cirrhotic Patients: A Single-Center Pilot Study
por: Scarpellini, E., et al.
Publicado: (2022)

Current Status and Future Therapeutic Options for Fecal Microbiota Transplantation
por: Tkach, Sergii, et al.
Publicado: (2022)

Impact of Immuno-Nutrition on the Nutritional Status, Inflammatory Response and Clinical Outcome of Clinic-Admitted Mild-Intensity-COVID-19 Patients: A Pilot, Perspective-Concluding Study
por: Basilico, Martina, et al.
Publicado: (2023)

The human gut microbiota and virome: Potential therapeutic implications
por: Scarpellini, Emidio, et al.
Publicado: (2015)

Gut microbiome and checkpoint inhibitor colitis
por: Sehgal, Kanika, et al.
Publicado: (2021)

Nutritional Support in Acute Liver Failure
por: Abenavoli, Ludovico, et al.
Publicado: (2022)

The mechanism of dysbiosis in alcoholic liver disease leading to liver cancer
por: Méndez-Sánchez, Nahum, et al.
Publicado: (2020)

Decompressive Craniectomy in Severe Traumatic Brain Injury: The Intensivist’s Point of View
por: Vitali, Matteo, et al.
Publicado: (2023)

An Exploratory Study for the Association of Gut Microbiome with Efficacy of Immune Checkpoint Inhibitor in Patients with Hepatocellular Carcinoma
por: Shen, Ying-Chun, et al.
Publicado: (2021)

Gut microbiome in modulating immune checkpoint inhibitors
por: Li, Xiang, et al.
Publicado: (2022)

Fecal Microbiota Transplantation in NAFLD Treatment
por: Abenavoli, Ludovico, et al.
Publicado: (2022)

Mild impact of SARS-CoV-2 infection on the entire population of liver transplant recipients: the experience of an Italian Centre based in a high-risk area
por: Mocchegiani, Federico, et al.
Publicado: (2020)

Eubiotic properties of rifaximin: Disruption of the traditional concepts in gut microbiota modulation
por: Ponziani, Francesca Romana, et al.
Publicado: (2017)

Gut microbiome modulates efficacy of immune checkpoint inhibitors
por: Yi, Ming, et al.
Publicado: (2018)

When the microbiome helps the brain‐current evidence
por: Drljača, Jovana, et al.
Publicado: (2023)

Overview of Immune Checkpoint Inhibitors Therapy for Hepatocellular Carcinoma, and The ITA.LI.CA Cohort Derived Estimate of Amenability Rate to Immune Checkpoint Inhibitors in Clinical Practice
por: Giannini, Edoardo G., et al.
Publicado: (2019)

Bariatric Surgery and Liver Disease: General Considerations and Role of the Gut–Liver Axis
por: Cerreto, Maria, et al.
Publicado: (2021)

Effect of Immuno-Nutrition on Malnutrition, Inflammatory Response and Clinical Course of Semi-Critically Ill COVID-19 Patients: A Pilot Perspective Study
por: Scarcella, Marialaura, et al.
Publicado: (2023)

Esophageal microbiome signature in patients with Barrett’s esophagus and esophageal adenocarcinoma
por: Lopetuso, Loris Riccardo, et al.
Publicado: (2020)

Food Emulsifiers and Metabolic Syndrome: The Role of the Gut Microbiota
por: De Siena, Martina, et al.
Publicado: (2022)

Editorial of Special Issues “Gut Microbiota–Host Interactions: From Symbiosis to Dysbiosis 2.0”
por: Zuccaro, Valentina, et al.
Publicado: (2023)

Effect of Whey Proteins on Malnutrition and Extubating Time of Critically Ill COVID-19 Patients
por: Scarcella, Marialaura, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9591avqedjkvquq388qb7hhf29